Mye-EUNITER
 

Karin, Nathan

Nathan Karin and his group focuses on exploring the role of chemokines and their receptors in the regulation of to type of diseases: T cell mediated autoimmunity (the key models in the lab are experimental autoimmune encephalomyelitis (EAE) and IBD) and the role of chemokines in shaping tumor microenviroment in immune-competent models of prostate cancer and of melanoma. The lab focuses now on the role of chemokines and their receptors in directing the mobilization and colonization of Myeloid cells in models of these cancer diseases.

Major cell types studied & key scientific question(s) for Mye-EUNITER

e key scientific question that Nathan Karin and his lab focuses on in cancer is on the role of chemokines on shapping tumor micromanagement (Izhak et al J. Immunol 2009, Izhak et al J. Immunol 2010, Izhak et al Plos One 2012). The lab now focuses on the role of chemokines and their receptors in directing the mobilization and colonization of Myeloid cells in models of these cancer diseases. As for T cell mediated autoimmunity the lab focuses on how chemokines direct the polarization of biological function of effector and regulatory cells (Zohar et al JCI 2014, Meiron et al JEM 2008). Recently  following the studies of Steve Miller and his group on Myeloid cells in EAE (Nature Immunology, 2007) NK and his lab began to be interested on the role of chemokines in directing the biological function of these cells in autoimmunity.

Technology available:

Nathan Karin and his laboratory are world leading in stabilizing chemokines as functional fusion proteins (Meiron et al JEM 2008 , Zohar et al JCI 2014) and also in generating functional chimeric soluble chemokine receptors ((Izhak et al J. Immunol 2009, Izhak et al J. Immunol 2010, Izhak et al Plos One 2012, Sapir et al J. Immunol 2010).
Specific Technologies
1. Mass Cytometry (Cytof).
2. Flow cytometry (10-color) (Zohar et al JCI 2014)
3. Cellular immunology- all basic technics + developing of antigen specific T cell line and clones (without immortalization) that could be used for adoptive transfer of autoimmunity and for discovery of new T cell subsets ( Wildbaum, Zohar and Karin Am J. Pathol 2010).
4. Immunohistochemistry, tissue microarrays (Zohar et al JCI 2014)
5. Luminex (we have just set it up, not published yet).
6. Cell separation technologies (including the use of FACSAREA cell sorter)

Key publications related to Mye-EUNITER:

1. Zohar, Y., et al. (2014). "CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis." J Clin Invest 124(5): 2009-2022.
2. Izhak, L., et al. (2010). "Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner." J Immunol 184(2): 1092-1101.
3. Meiron, M., et al. (2008). "CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells." J Exp Med. 205(11): 2643-2655.
4. Wildbaum, G., et al. (2003). "Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity." Immunity 19: 679-688.
5. Yednock, T. A., et al. (1992). "Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin." Nature 356(6364): 63-66.

 

Contact details:

Department of Immunology
Rappaport Inst.
Rappaport Faculty of Medicine,
Technion,
P.O.B. 9697,
Haifa 31096, Israel.

972-4-8295232

nkarin@tx.technion.ac.il